Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (2021 - 2026)

Indivior Pharmaceuticals has reported Shares Outstanding over the past 6 years, most recently at $122.0 million for Q1 2026.

  • For Q1 2026, Shares Outstanding fell 2.4% year-over-year to $122.0 million; the TTM value through Mar 2026 reached $122.0 million, down 2.4%, while the annual FY2025 figure was $125.0 million, 0.0% changed from the prior year.
  • Shares Outstanding for Q1 2026 was $122.0 million at Indivior Pharmaceuticals, down from $125.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $137.0 million in Q4 2023 and troughed at $122.0 million in Q1 2026.
  • A 5-year average of $129.1 million and a median of $125.0 million in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: tumbled 80.63% in 2022 and later rose 0.74% in 2023.
  • Year by year, Shares Outstanding stood at $136.0 million in 2022, then increased by 0.74% to $137.0 million in 2023, then decreased by 8.76% to $125.0 million in 2024, then changed by 0.0% to $125.0 million in 2025, then fell by 2.4% to $122.0 million in 2026.
  • Business Quant data shows Shares Outstanding for INDV at $122.0 million in Q1 2026, $125.0 million in Q4 2025, and $125.0 million in Q3 2025.